NewCardio's CardioBip technology for remote wireless monitoring demonstrates reliable detection of AF

NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic technology provider, announced today that the Heart Rhythm Society (HRS) has accepted an abstract detailing the superior performance of NewCardio's patented CardioBip™ technology for remote wireless monitoring and detection of atrial fibrillation (AF). The study results, which discuss the use of CardioBip for improved AF monitoring and detection, are scheduled for oral presentation at the Heart Rhythm Society 31st Annual Scientific Sessions, May 12-15, 2010, in Denver, Colorado.

The abstract, titled "Three-dimensional Atrial Signal Reconstruction Facilitates Remote Detection Of Atrial Fibrillation," was written by Alexei Shvilkin, MD, PhD, Dejan Vukajlovic, MD, Vladan Vukcevic, MD, Ihor Gussak, MD, PhD, Bosko Bojovic, PhD, Uros Mitrovic, MS and Goran Simic, MS. The abstract highlights a new AF detection algorithm based on NewCardio's proprietary 3-D ECG processing platform.

Alexei Shvilkin, MD, PhD, of Beth Israel Deaconess Medical Center and Harvard Medical School, the abstract's first author and principal investigator, commented, "Reliable detection of AF represents an important clinical objective that could improve outcomes for remotely monitored patients. Because of the low amplitude of atrial electrical activity and noise associated with use of remote monitoring, current systems predominantly rely on heart rate variability to detect AF. As a result, some patients may be misdiagnosed, especially those undergoing post-ablation AF monitoring. In this study, we showed that NewCardio's CardioBip-based wireless technology enables the assessment of atrial activity by using ensemble signal processing, 12-lead ECG reconstruction, and 3-D processing of atrial activity. The new algorithm detects the difference in atrial activity between AF and sinus rhythm and does not rely on heart rate variability measurements. It has the potential to improve patient monitoring outcomes by differentiating AF from other confounding arrhythmia (e.g. atrial flutter, atrial tachycardia) that may occur after AF ablation."

Mark Kroll, PhD, Fellow of the HRS and NewCardio's Chairman of the Board of Directors, added, "We are excited to share this important clinical advancement with scientists, medical professionals and industry leaders at the HRS Annual Scientific Sessions. We are grateful that the HRS accepted this abstract for oral presentation. This provides the Company with added confidence in the science behind its solutions for chronic care."

The CardioBip is a unique, hand-held device that provides a solution for ECG remote monitoring. Patients can carry the CardioBip with them and use it to generate and transmit synthesized, accurate 12-lead ECGs at physician prescribed intervals of time, during ordinary daily activity or when symptoms develop. What makes CardioBip unique is its extreme ease of use, combined with the ability to generate recordings substantially equivalent in quality with standard 12-lead ECGs. The CardioBip works without any cables, cumbersome leads, wires or inconvenient skin electrodes, as the device's electrodes are integrated, offering potential compatibility with popular hand-held PDA platforms. On January 12, 2010, the U.S. Patent and Trademark Office issued patent 7,647,093, titled "Apparatus and method for cordless recording and telecommunication transmission of three special ECG leads and their processing." This represents the core patent for CardioBip.

SOURCE NewCardio, Inc.